secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019170
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q1 net loss widens to $17.7M; in-licenses CRB-701 Nectin-4 ADC
---------------------------------------------------------------------

- Net loss of $17.7M ($4.24 per share) vs $9.4M ($2.26) in Q1 2022.
- Operating expenses rose $8.8M to $17.3M, driven by $7.5M CRB-701 license upfront.
- Cash and investments $44.2M; runway expected through Q2 2024.
- In-licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 in China, US trial by mid-2024.
- CRB-601 IND on track for H2 2023; Dr. Yong Ben appointed to board March 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/0000950170-23-019170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/crbp-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer